Besides being Canada's particle accelerator centre with emphasis on nuclear, particle and accelerator physics, TRIUMF has a long history of medical isotope production and radiotherapy. The Life Sciences Division produces PET tracers for the local hospitals for over 40 years. Recently, we have taken on the challenge to expand our isotope repertoire by utilizing the full range of cyclotrons at TRIUMF, from 13 MeV to 500 MeV proton energy. Next to the traditional PET isotopes F-18 and C-11, we are now producing radiometals for SPECT and PET in innovative liquid and solid targets. We also added auger and alpha emitters to the list that can be fashioned into therapeutic cancer radiopharmaceuticals. In addition, radiotherapy for cancer treatment has been a long-standing commitment at TRIUMF, first with pion therapy and then with proton therapy, for many years operating Canada's only proton therapy facility. To improve treatment with protons, we have established new beam-shaping methodologies by employing additive manufacturing, are investigating new detectors for proton dosimetry, and are researching in-vivo range verification in real time.
Cornelia Hoehr received her Ph.D. in physics from Heidelberg University in Germany and the Max-Plank institute for Nuclear Physics in Heidelberg. After a post-doctoral research term at the Argonne National Lab, USA, she then moved to TRIUMF as a post-doctoral researcher, and subsequently took on roles in operation and facilities in isotope production and proton therapy. In 2013 she became a research scientist at TRIUMF and an Adjunct Professor at the University of Victoria, and in 2018 she became Adjunct at the University of British Columbia and took over the role as Deputy Associate Laboratory Director – Life Sciences at TRIUMF. Her research interests are focused on medical isotope production and proton therapy. She is a member of the steering committee for the Particle Therapy Co-Operative Group (PTCOG), consultant to the IAEA in isotope production, and was chair of the TRIUMF User Group Executive Committee (TUEC).